Paid episode

The full episode is only available to paid subscribers of Courageous Discourse™ with Dr. Peter McCullough & John Leake

BREAKING--Infant Mortality Concern Emerges with Nirsevimab RSV Monoclonal Antibody Given to Newborns

Dr. Helene Banoun Reports Imbalance from RCTs and Emerging Signal from Real World French Data

By Peter A. McCullough, MD, MPH

Respiratory syncytial virus (RSV) is a common viral infection affecting infants (~3.6 million total population) mainly under age 1 year easily treated with nebulizer therapy. Urgent care, emergency room, and hospitalization can occur for serious cases and if treated early, infant mortality should not be a concern. Among the 22.4 million children under age 5 years, the annual risk of RSV hospitalization is well under 1%. The CDC estimates 100-300 RSV deaths per year under age 5 years. Likely most would be avoided with early albuterol/budesonide nebulization therapy at home.

The Bio-Pharmaceutical Complex has targeted RSV as we emerge from the pandemic as a viral threat to propagandize young parents in an all-out war against the virus. Incredibly there are prefusion antigen vaccines for pregnant mothers and adults who do not have significant risks for the disease and now Nirsevimab (Beyfortis, Sanofi, AstraZeneca) monoclonal antibodies are widely endorsed and given on the first day of life in the US since October, 2023, with no long-term safety data.

CDC.Gov accessed December 27, 2023

Continue reading this post for free, courtesy of Peter A. McCullough, MD, MPH.